Clinical Trials Browser

Withdrawn × Magnetic Resonance Spectroscopy × 90 days × Clear all

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

Phase 1 Withdrawn

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms